Associated Papers
Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database.
Sini C et al.
European Journal of Cancer (oxford, England : 1990), 2026
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
The pathogenic mutations in smokers with non-small cell lung cancer: a next-generation sequencing study.
Yan S et al.
Translational Lung Cancer Research, 2025
[A Case of Metastatic Non-small Cell Lung Cancer with Rare BRAF p.L485_T488delinsF Mutation Treated with Dabrafenib and Trametinib].
Wang Y et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2025
Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands.
de Bitter TJJ et al.
Scientific Reports, 2025
Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies.
Waliany S et al.
Clinical Lung Cancer, 2025
Assessing mutation-clinical correlations and treatment outcomes in Vietnamese non-small cell lung cancer patients.
Nguyen HB et al.
Practical Laboratory Medicine, 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients.
van der Leest P et al.
Communications Medicine, 2025
Germline DNA Repair Gene Mutations and Clonal Hematopoiesis (CH) in 24,849 Patients with BRCA-Associated Cancers.
Marshall CH et al.
Cancers, 2025
Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States.
George SL et al.
Cancer Discovery, 2025
BRAF V600E in cancer: Exploring structural complexities, mutation profiles, and pathway dysregulation.
Bharti J et al.
Experimental Cell Research, 2025
Genomic Landscapes of Early-Onset Versus Average-Onset Colorectal Cancer Populations.
Storandt MH et al.
Cancers, 2025
DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer.
Tan S et al.
Cancer, 2025
Transdifferentiation of Multiple Myeloma into Histiocytic Sarcoma: Case Report of a Highly Unusual Phenomenon.
Seth N et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology, 2025
Effects of chemotherapy combined with immunotherapy for non-small cell lung cancer with BRAF-mutations: a retrospective study.
Sun X et al.
American Journal of Cancer Research, 2025
The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs).
Zhang L et al.
Elife, 2024
Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.
Bortolot M et al.
International Journal of Molecular Sciences, 2024
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.
Vasseur D et al.
Molecular Cancer, 2024
Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Li Y et al.
Esmo Open, 2024
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.
Park C et al.
Cancer Immunology, Immunotherapy : Cii, 2024
An updated literature on BRAF inhibitors (2018-2023).
Maji L et al.
Molecular Diversity, 2024
The Pan-RAF-MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS-MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers.
Ryan MB et al.
Cancer Discovery, 2024
Pathways and targeting avenues of BRAF in non-small cell lung cancer.
Imyanitov EN et al.
Expert Opinion on Therapeutic Targets, 2024
A comprehensive overview of the molecular features and therapeutic targets in BRAFV600E-mutant colorectal cancer.
Gu R et al.
Clinical and Translational Medicine, 2024
Accelerated drug-resistant variant discovery with an enhanced, scalable mutagenic base editor platform.
Dorighi KM et al.
Cell Reports, 2024
Oncogene-Driven Non-Small Cell Lung Cancers in Patients with a History of Smoking Lack Smoking-Induced Mutations.
Huang CY et al.
Cancer Research, 2024
Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study.
Zhou H et al.
Discover Oncology, 2024
A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance.
Scaini MC et al.
Npj Precision Oncology, 2024
BRAF - a tumour-agnostic drug target with lineage-specific dependencies.
Hanrahan AJ et al.
Nature Reviews. Clinical Oncology, 2024
Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial.
Shimoi T et al.
Eclinicalmedicine, 2024
A Challenging Correlation between Tumor Cellularity and Somatic Variant Allele Fraction in Lung and Colorectal Cancers-Specimens of Low Tumor Percentage Should Be Analyzed with Caution.
Zarabi SK et al.
Biomolecules, 2024
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers.
Kazandjian S et al.
Cancers, 2024
Clinical impact of mixed pulmonary carcinoma and carcinoid: the driver from their mono-clonal origin.
Graziano P et al.
Virchows Archiv : an International Journal of Pathology, 2024
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
Tang TY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation.
Ambrosini-Spaltro A et al.
Current Oncology (toronto, Ont.), 2023
BRAF mutations and concurrent alterations in patients with soft tissue sarcoma.
Kobayashi H et al.
Genes, Chromosomes & Cancer, 2023
Identification of an optimal mutant allele frequency to detect activating KRAS, NRAS, and BRAF mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomas.
Caughey BA et al.
Journal of Gastrointestinal Oncology, 2023
Unique Spectrum of Activating BRAF Alterations in Prostate Cancer.
Chehrazi-Raffle A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Clinical significance of genetic profiling based on different anatomic sites in patients with mucosal melanoma who received or did not receive immune checkpoint inhibitors.
Wang HY et al.
Cancer Cell International, 2023